Clorox (CLX) Beats Q4 Earnings & Sales Estimates, Stock Down

The Clorox Company CLX has reported robust fourth-quarter fiscal 2020 results, wherein earnings and sales beat the Zacks Consensus Estimate and grew year over year. Robust demand for disinfecting and cleaning products due to the coronavirus outbreak, and broad-based growth at all segments primarily aided results. Also, the company’s IGNITE strategy and product portfolio bode well. The factors also position it well for the future. Moreover, the company outlined its fiscal 2021 view.

Despite strong fiscal fourth-quarter results, shares of Clorox declined 2.8% in the pre-market session. In the past three months, shares of this Zacks Rank #2 (Buy) company have rallied 18.7% compared with the industry’s 15.9% growth.



Q4 Highlights

Quarterly earnings from continuing operations of $2.41 per share increased about 28% year over year and beat the Zacks Consensus Estimate of $2.00. The upside was mainly driven by higher net sales and gains from cost-savings, which aided margins. Nonetheless, increased selling and administrative costs, manufacturing and logistics costs, and advertising investments partly hurt the bottom line.

The company posted net sales of $1,983 million, up nearly 22% year over year and surpassing the Zacks Consensus Estimate of $1,858 million. This was backed double-digit volume growth across all segments, fueled by strong demand for its products due to the coronavirus outbreak and the stay-at-home trend. However, growth was partly offset by 2 points of adverse foreign currency impact. Organic sales increased 24% in the quarter.

The Clorox Company Price, Consensus and EPS Surprise


The Clorox Company Price, Consensus and EPS Surprise

The Clorox Company price-consensus-eps-surprise-chart | The Clorox Company Quote

Gross margin expanded 170 basis points (bps) to 46.8% in the fiscal fourth quarter. This marked the company’s seventh straight quarter of gross margin expansion. The rise in gross margin was driven by gains from cost savings and double-digit volume growth, somewhat marred by higher expenses for manufacturing and logistics.

Segmental Discussion

In fourth-quarter fiscal 2020, the company realigned its Cleaning segment through operational and systems integration. The segment is now called Health and Wellness. As part of the operational and system integration, the company’s Digestive Health and Dietary Supplements business units were combined into a new business unit named Vitamins, Minerals and Supplements, while the Laundry and Home Care business units were combined to create the Cleaning business unit. These two newly formed business units as well as the Professional Products business unit collectively make the company’s new Health and Wellness segment.

Sales of the Health and Wellness segment rose 33% at $805 million on double-digit growth in two of the aforesaid three business units. Robust gains from the increased demand for disinfecting and cleaning products across the Cleaning and Professional Products units due to COVID-19 were the primary growth drivers.

The Household segment’s sales rose 17% to $612 million, driven by growth across all business units. Particularly, the company witnessed strong double-digit growth in Bags and Wraps, and Grilling businesses, owing to a much stronger consumer demand, aided by innovation.

Sales at the Lifestyle segment grew 16% to $298 million on double-digit sales growth in the Food and Water Filtration businesses, owing to strong consumer demand.

At the International segment, sales increased 12% to $268 million from the year-ago quarter on robust demand for cleaning and disinfecting products as well as other household items. Though sales were hurt by 12 points of negative currency impact, this was partly mitigated by strong pricing action implemented prior to the pandemic. Organic sales for the segment rose 24%.


Clorox ended fiscal 2020 with cash and cash equivalents of $871 million, and long-term debt of $2,780 million. In fiscal 2020, the company generated $1.5 billion of net cash from continuing operations.

Fiscal 2021 Guidance

Though there remains uncertainty about the future business trends, owing to the COVID-19 outbreak, Clorox provided its outlook for fiscal 2021 based on the current trends and some assumptions. These include persistent strong demand globally for cleaning and disinfecting products, aggressive investments in its global portfolio, discretionary pressures on consumers due to the ongoing recession, and minimal disruptions in its extended supply chain and other operations.

Backed by the factors, the company predicts flat to low-single-digit sales growth in fiscal 2021. This is likely to be driven by the persistence of elevated consumer demand through the first half of fiscal 2021, followed by a decelerating demand in the second half on the lapping of the initial spike in demand due to the COVID-19 outbreak in the second half of fiscal 2020. Organic sales for fiscal 2021 are expected to be flat to up in low-single digits.

Moreover, advertising and sales promotion spending is anticipated to increase to 11% of sales. Selling and administrative expenses are projected to be 14% of sales. The company envisions effective tax rate of 22-23% for fiscal 2021.

Management anticipates fiscal 2021 earnings per share between a mid-single-digit decline and a mid-single-digit rise. Moreover, earnings per share are expected to include 45-53 cents of contribution from its recently increased stake in the Kingdom of Saudi Arabia joint venture. This one-time non-cash gain due to fair value adjustments of the previously held stake is expected to be recorded in first-quarter fiscal 2021.

Other Top-Ranked Stocks to Consider

Nu Skin Enterprises, Inc. NUS has an expected long-term earnings growth rate of 10.7% and it sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Helen of Troy Limited HELE has an expected long-term earnings growth rate of 6.5% and it currently flaunts a Zacks Rank #1.

The Procter Gamble Company PG has a long-term earnings growth rate of 7.2%. It presently carries a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Procter Gamble Company The (PG): Free Stock Analysis Report
The Clorox Company (CLX): Free Stock Analysis Report
Helen of Troy Limited (HELE): Free Stock Analysis Report
Nu Skin Enterprises, Inc. (NUS): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.